TRIB2 and the ubiquitin proteasome system in cancer

Salome, M. , Campos, J. and Keeshan, K. (2015) TRIB2 and the ubiquitin proteasome system in cancer. Biochemical Society Transactions, 43(5), pp. 1089-1094. (doi:10.1042/bst20150103) (PMID:26517929)

[img]
Preview
Text
112600.pdf - Accepted Version

327kB

Abstract

Tribbles family of pseudokinase proteins are known to mediate the degradation of target proteins in Drosophila and mammalian systems. The main protein proteolysis pathway in eukaryotic cells is the ubiquitin proteasome system (UPS). The tribbles homolog 2 (TRIB2) mammalian family member has been well characterized for its role in murine and human leukaemia, lung and liver cancer. One of the most characterized substrates for TRIB2-mediated degradation is the myeloid transcription factor CCAAT enhancer binding protein α (C/EBPα). However, across a number of cancers, the molecular interactions that take place between TRIB2 and factors involved in the UPS are varied and have differential downstream effects. This review summarizes our current knowledge of these interactions and how this information is important for our understanding of TRIB2 in cancer.

Item Type:Articles
Additional Information:The final version of record is available at http://www.biochemsoctrans.org/content/43/5/1089
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Keeshan, Dr Karen and Salome, Ms Mara and Campos, Ms Joana
Authors: Salome, M., Campos, J., and Keeshan, K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Biochemical Society Transactions
Publisher:Portland Press Ltd.
ISSN:0300-5127
ISSN (Online):1470-8752
Copyright Holders:Copyright © 2015 The Authors
First Published:First published in Biochemical Society Transactions 43(5):4089-1094
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
647983CR-UK Centre renewalKaren VousdenCancer Research UK (CAN-RES-UK)C596/A18076RI CANCER SCIENCES